Melissa K. Accordino
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (12)
Purpose: PIK3CA mutations frequently drive solid tumors, particularly hormone receptor–positive breast cancer. Inavolisib, an ATP-competitive p110α inhibitor, also promotes the degradation of mutated p110α. PI3K inhibitors have generally shown modest single-agent activity and have safety concerns. Patients and Methods: A first-in-human phase 1 study (NCT03006172) evaluated oral inavolisib in patients with PIK3CA -mutated solid tumors to determine the maximum tolerated dose and safety. Correlative analyses included ctDNA. Preclinical studies in cell lines and xenografts elucidated the role of FGFR2. Results: The maximum tolerated dose was 9 mg daily, with a manageable safety profile (e.g., hyperglycemia and diarrhea). Inavolisib showed linear pharmacokinetics, consistent pharmacodynamic modulation, and antitumor activity in hormone receptor–positive PIK3CA -mutated breast cancer (26% objective response rate and 45% clinical benefit rate). FGFR2 hotspot mutations in ctDNA were strongly associated with clinical benefit. Preclinically, oncogenic FGFR2 signaling enhanced inavolisib sensitivity by engaging HER3, RAS, and p85β, that facilitated mutated p110α degradation, surpassing nondegrading inhibitors. Combination therapy with FGFR2 inhibitors showed synergy and delayed resistance. Conclusions: These findings highlight a novel cooperativity between FGFR2 and p110α that boosts the effectiveness of inavolisib. The data support advancing precision oncology beyond single biomarkers to complex algorithms utilizing co-occurring alterations, suggesting that combining inavolisib with FGFR2 inhibitors may offer enhanced and more durable responses in PIK3CA/FGFR2 -altered tumors.
Year:
2026
Summary of enrollment for the N of 1 trial to date, including numbers by cancer type, the attempt to develop a PDX, establishment of PDX, RNASeq/VIPER profiling of PDX when established, and completion of drug testing.
Year:
2025
Comprehensive list of clinically relevant drugs screened in cell lines (not all were available at time of study). The list is divided into three sections, including one with FDA approved antineoplastics, one with experimental antineoplastics in clinical trials, and one with non-antineoplastics and tool compounds selectively screened when demonstrating an EC50
Year:
2025
Detailed summary of therapeutic response at end-of-study time point, organized by study group—OncoTreat, OncoTarget, or Negative control—and then stratified by each individual drug arm. The study was underpowered for statistical analyses of therapeutic response in individual drug arms.
Year:
2025
PURPOSE To identify geographic areas and populations in the United States likely to experience challenges accessing cancer care. METHODS We tabulated the number of hematologists and medical oncologists billing Medicare nationally, by state, and by county in 2014, 2019, and 2024, and assessed trends over time, offset by the US population age 55 years and older (where 80% of new cancers are diagnosed). We identified counties with oncologist presence, those with ≥25% of oncologists in late-career phases that could face reduced oncology care coverage in the future, as well as counties adjacent and nonadjacent to counties with oncologists, and outlined differences in populations residing in those counties. We characterized the current oncologist workforce by demographics and features of where they practice, stratified by career stage. RESULTS As the number of oncologists increased from 12,267 in 2014 to 14,547 in 2024, the number per 100,000 population age 55 years and older decreased from 15.9 to 14.9. In 2024, 38 states had fewer oncologists per capita than in 2014, with most facing limited rural workforce coverage. Although 89% of the population lived in counties with oncologists, 68% of the population lived in counties where more than a quarter of oncologists were nearing retirement age. Early-career clinicians were less likely than their later-career counterparts to work in counties that were rural or had high rates of cancer mortality, smoking, obesity, social vulnerability, uninsurance, and homes without broadband Internet access. CONCLUSION Gaps in oncologist coverage across the country exist, especially among rural populations and those with high cancer burden and socioeconomic risk. Understanding the geographic coverage of oncologists could facilitate efforts to improve patient access to cancer care.
Year:
2025
Summary of enrollment for the N of 1 trial to date, including numbers by cancer type, the attempt to develop a PDX, establishment of PDX, RNASeq/VIPER profiling of PDX when established, and completion of drug testing.
Year:
2024
Detailed summary of therapeutic response at end-of-study time point, organized by study group—OncoTreat, OncoTarget, or Negative control—and then stratified by each individual drug arm. The study was underpowered for statistical analyses of therapeutic response in individual drug arms.
Year:
2024
Detailed summary of therapeutic response at end-of-study time point, organized by study group—OncoTreat, OncoTarget, or Negative control—and then stratified by each individual drug arm. The study was underpowered for statistical analyses of therapeutic response in individual drug arms.
Year:
2024
Summary of enrollment for the N of 1 trial to date, including numbers by cancer type, the attempt to develop a PDX, establishment of PDX, RNASeq/VIPER profiling of PDX when established, and completion of drug testing.
Year:
2024
Comprehensive list of clinically relevant drugs screened in cell lines (not all were available at time of study). The list is divided into three sections, including one with FDA approved antineoplastics, one with experimental antineoplastics in clinical trials, and one with non-antineoplastics and tool compounds selectively screened when demonstrating an EC50
Year:
2024
Year:
2024
Year:
2023
Collaborators (34)
Helen M. Parsons
University of Minnesota
Joseph G. Jurcic
Columbia University Irving Medical Center
Prabhjot Mundi
Assistant Professor
Columbia University Irving Medical Center
Peter Sims
Assistant Professor
Columbia University Irving Medical Center
Hanina Hibshoosh
Professor of pathology at CUIMC
Columbia University
Melissa Ronan
Broad Institute
Guy M. McKhann
Florence Irving Associate Professor of Neurological Surgery
Columbia University Irving Medical Center
Danilo Maddalo
Group Leader
Genentech Inc
Ana Tergas
Rutgers, The State Univ. of NJ
Kenneth Olive
Assistant Dean of Graduate Curricula and Associate Professor of Medicine
Columbia University Irving Medical Center
Guarionex Joel DeCastro
Associate Professor
Columbia University
Jason D. Wright
-
Andrew Kung
Chair
Memorial Sloan Kettering Cancer Center
Mariano Alvarez
Chief Scientific Officer
KweHealth, LLC
Gary K. Schwartz
Case Western Reserve University
Andrew Lassman
Chief, Neuro-Oncology Division
Columbia University Irving Medical Center
Dawn L. Hershman
Columbia University Irving Medical Center
Andrés Cervantes
Professor of Medicine
University of Valencia
Philippe L. Bedard
University Health Network
Kevin Kalinsky
Emory University
Peter Schmid
Professor of Cancer Medicine and Honorary Consultant in Medical Oncology, Centre Lead, Centre for Experimental Cancer Medicine
Barts Cancer Institute
Katherine Crew
Professor
Columbia University Irving Medical Center
Alfred I. Neugut
-
Daniel Diolaiti
Fred Hutchinson Cancer Research Center
Antoine Italiano
Université Paris-Saclay
Michael Kluger
Professor of Surgery
NYU Langone Health
Andrea Califano
Columbia University Irving Medical Center
Eugene Douglass
Assistant Professor
University of Georgia
Catherine Shu
Columbia University Irving Medical Center
Valentina Gambardella
INCLIVA Health Research Institute
Manali I. Patel
Stanford University School of Medicine
Cristina Saura Manich
Associate Professor
Universitat Autònoma de Barcelona (UAB)
Jennifer Roth
Broad Institute
Jeffrey Bruce
NewYork-Presbyterian Hospital/Columbia University Irving Medical Center
Make your next move.
Prepare your application
Review drafts before you send them.